Published in final edited form as:

Biochemistry. 2011 April 12; 50(14): 2829–2837. doi:10.1021/bi101701x.

Differential Response to Morphine of the Oligomeric State of μ -Opioid in the Presence of δ -Opioid Receptors[†]

Urszula Golebiewska¹, Jennifer M. Johnston², Lakshmi Devi³, Marta Filizola², and Suzanne Scarlata^{4,*}

¹ Department of Biological Sciences and Geology, Queensboro Community College, Bayside, New York 11364-1497

² Department of Structural and Chemical Biology, Mount Sinai School of Medicine, New York, NY 10029

³ Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY 10029

⁴ Department of Physiology & Biophysics, Stony Brook University, Stony Brook, New York 11794-8661

Abstract

Prolonged morphine treatment induces extensive desensitization of the μ -opioid receptor (μ OR) which is the G protein-coupled receptor that primarily mediates the cellular response to morphine. To date, the molecular mechanism underlying this process is unknown. Here, we have used live cell fluorescence imaging to investigate whether prolonged morphine treatment affects the physical environment of μ OR, or its coupling with G proteins, in two neuronal cell lines. We find that chronic morphine treatment does not change the amount of enhanced yellow fluorescence protein (eYFP)-tagged μ OR on the plasma membrane, and only slightly decreases its association with G protein subunits. Additionally, morphine treatment does not have a detectable effect on the diffusion coefficient of eYFP- μ OR. However, in the presence of another family member, the δ -opioid receptor (δ OR), prolonged morphine exposure results in a significant increase in the diffusion rate of μ OR. Number and brightness measurements suggest that μ OR exists primarily as a dimer that will oligomerize with δ OR into tetramers, and morphine promotes the dissociation of these tetramers. To provide a plausible structural context to these data, we used homology modeling techniques to generate putative configurations of μ OR- δ OR tetramers. Overall, our studies provide a possible rationale for morphine sensitivity.

Opioid receptors are seven-transmembrane (TM) G protein-coupled receptors (GPCRs). They can be classified into three major subfamilies, μ OR, δ OR, and κ OR, which mediate different physiological functions, and which vary in their tissue distribution. With the exception of a few selective compounds, all opioid receptors are capable of binding to the same endogenous ligands, such as dynorphins, enkephalins, endorphins, as well as the same

[†]This work was supported by NIH GM053132 (SS), GM071558 (SS and LD), DA020032 (MF) DA026434 (MF), and DA008863 and DA019521 (LD).

*Corresponding author: S. Scarlata, Dept. Physiol. Biophysics, Stony Brook University, Stony Brook, NY 11794-8661, 631-444-3071, 631-444-3432 FAX Suzanne.Scarlata@sunysb.edu.

Supporting Material. In the supporting material, we present a cytosolic view of a homology model of active μ OR superimposed on a model of the inactive form. This figure highlights the change in orientation of R165 and T279 when the receptor becomes activated. This figure may be accessed free of charge online at <http://pubs.acs.org>.

exogenous ligands, such as morphine and other analgesics (1). Opioid receptors bind to these different ligands with different affinities, thus generating varying cellular responses.

Opioid receptors are seven-transmembrane (TM) G protein-coupled receptors (GPCRs) and are coupled to the $G\alpha_i$ family of heterotrimeric G proteins. The main cellular effect of $G\alpha_i$ activation is inhibition of adenylyl cyclase resulting in reduced levels of intracellular cAMP (for reviews see (2–4)). In general, after a ligand binds to its specific GPCR, the receptor is phosphorylated by a receptor kinase, where it then clusters on the membrane surface, and internalizes into endosomes to quench the signal. However, this is not the case for morphine stimulation of μ OR. Prolonged treatment of cells with morphine diminishes its elicited response without significant internalization (i.e. no significant decrease in the amount of receptor on the plasma membrane). The mechanism(s) that underlies this unique desensitization behavior is not well understood but appear to be a combination of many cellular events. Desensitization may involve changes in proteins that regulate receptor phosphorylation and internalization (see (1)) and may also involve decoupling between receptors and G proteins (see (5)).

Opioid receptors, like other GPCRs, appear to associate into dimers and higher order oligomers which may alter their ligand binding and G protein activation (6,7). Coimmunoprecipitation and bioluminescence resonance energy transfer studies suggest that μ OR physically associates with δ OR when the two receptors are co-expressed (8,9), although recent studies in mice suggest the two receptors may have distinct localization and activators (10). It has been found that chronic morphine upregulates μ OR- δ OR dimers (11) and that activation of the δ OR subunit of δ OR- μ OR dimers leads to increased μ OR degradation and a reduced cellular response (12). The mechanism that underlies this enhanced degradation is unclear.

Here, we report on the changes in the interaction between μ OR and its attached G proteins following prolonged morphine treatment, and the influence of δ OR on these interactions. We used Förster resonance energy transfer (FRET) to measure changes in association between receptors and G proteins, fluorescence correlation spectroscopy (FCS) to measure mobility of the receptors and G protein subunits, and number and brightness (N&B) analysis to monitor the degree of receptor oligomerization. Additionally, we used computational modeling to offer a structural interpretation of the experimental data.

We find that morphine has little effect on the diffusion properties of μ OR alone, or its interaction with G proteins. However, in the presence of δ OR, morphine treatment affects the extent of oligomerization of μ OR, as well as association of μ OR with G proteins. Taken together, these findings show how the functional properties of μ OR are correlated with its oligomerization.

MATERIALS AND METHODS

Materials

Fluorescent-labeled opioid receptors have been previously described (13). Fluorescent-tagged G proteins were a gift from Catherine Berlot (Gesinger Institute, Lewisburg, PA) and have been well characterized (14–17), and the double eGFP construct was a gift from Dr. Enrico Gratton (Laboratory of Fluorescence Dynamics, Univ. California, Irvine).

Cell Culture and Transfection

HEK293 and SK-N-SH cells were grown in modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 50 units/ml of penicillin and 50 μ g/ml of streptomycin sulfate. Neuro2a cells were grown in DMEM and F12 media (50:50)

supplemented with 10% FBS and 50 units/ml of penicillin and 50 µg/ml of streptomycin sulfate. Cells were maintained at 37 °C in a 5% CO₂ incubator. Neuro-2a and SK- N-SH cells were transfected using Lipofectamine per the manufacturer's protocol (Invitrogen). HEK-293 cells were transfected using calcium phosphate co-precipitation method. For FRET measurements cells were transfected with 5 µg of enhanced yellow fluorescent protein (eYFP)-µOR, 5µg eCFP-Gβ1 and 10µg of HAGγ7 or 5 µg of enhanced cyan fluorescent protein (eCFP)-µOR and 5µg eYFP-Gαi. We have previously estimated that this amount of DNA results in a three-fold amount of overexpressed over endogenous G protein subunits in HEK293 cells (18). Cells expressing low amounts of proteins were selected for viewing and we note that FCS and N&B measurements can only be done for ≥20 fluorescent molecules. For FCS and N&B measurements, cells were transfected with 2 µg of enhanced green fluorescent protein (eGFP)-µOR and, when noted, with 5 µg myc tagged δOR. Prior to fluorescence measurements transfected cells were washed and imaged in phenol free Libovitz 15 media.

In vivo single cell FRET measurements

In vivo FRET experiments were performed on Zeiss LSM 510 Meta/confocor2 apparatus (Jena, Germany) using synthesized emission method and have been previously described (see (19)). We used a 40 × NA 1.2 C-Apochromat water immersion objective and following filter settings: eCFP excitation: 458 nm line of argon ion laser and emission: 475–525 nm band pass filter, eYFP was excitation: 514 nm line of argon ion laser and emission: 560–615 nm band pass filter, and FRET excitation: 458 nm and emission: 560–615 nm band pass filter. Bleed through from eCFP fluorescence into the FRET channel and direct excitation of eYFP by the 458nm laser line values were estimated from cells transfected with eYFP-µOR and eCFP-Gβ1/HAGγ7 separately and imaged under the appropriate filter sets. The maximum FRET value was determined from control cells transfected with construct composed of eCFP and eYFP sandwiched between a 12 amino acid peptide.

After background subtraction NFRET values were calculated for every pixel in the image according to formula:

$$NFRET = \frac{I_{FRET} - a \times I_{YFP} - b \times I_{CFP}}{\sqrt{I_{YFP} \times I_{CFP}}}$$

where *a* is the percentage of bleed-through of eCFP through FRET filter set and *b* is the percentage of direct excitation of eYFP by 458 nm light (20).

Fluorescence correlation spectroscopy measurements

FCS measurements were performed on a Zeiss LSM 510 Meta/Confocor 2 apparatus (Jena, Germany) using standard configurations and minimal laser powers to avoid photobleaching of the fluorescent probes. All measurements were performed at room temperature. We used a 40 × NA 1.2 C-Apochromat water immersion objective and adjusted pinholes at least daily. We excited eGFP with the 488 nm line of argon ion laser and collected emission spectra through a 505 LP filter. We calibrated the detection volume by measuring the diffusion of rhodamine (Rh6G, $D = 4.2 \times 10^{-6}$ cm²/s) in water (Rutinger 2008, Petrasek 2008,). The radius of the detection volume for the 488 nm line was $r = 0.17 \pm 0.01$ µm. We rejected measurements that showed abrupt and significant changes in the count rate to avoid artifacts due to bleaching and/or cell movement. We used Sigma Plot and a least-squares algorithm to fit the autocorrelation curves to the model equation for free Brownian diffusion in two dimensions commonly used in FCS (21):

$$G(\tau) = \frac{1}{N} \cdot \sum_i \frac{Y_i}{1 + \frac{\tau}{\tau_{d,i}}}$$

where N is number of molecules in the detection volume, Y_i is a fraction of molecules diffusing with diffusion coefficient D_i producing residence times $\tau_{d,i} = r^2/4D_i$. We calculated the diffusion coefficient, D, from the Einstein relation:

$$D = \frac{r^2}{4\tau_d}$$

Number and brightness measurements

Confocal images were collected on an Olympus Fluoview 1000 LSCM fitted with a 60× PlanApo (1.40 NA) oil immersion objective. The analog/digital hybrid detector (PMT) was used in photon counting mode with 1× gain and 0% offset. Images of cells were collected with resolutions of 46 nm/pixel. A region of interest (256 × 256 box) was analyzed from an image of 512 × 512 pixels. The pixel dwell time was 12.5 μs/pixel and the pinhole diameter was 200 μm. eGFP was excited with the 0.1 % of 488-nm line of a 40 mW argon ion laser. In general 100 images of one cell were collected. Data analysis was done using the N&B analysis screen of the SimFCS program (www.lfd.uci.edu) (22). The offset and the readout noise were determined from the histograms of dark count performed after every measurement (100 images collected with the laser turned off).

Statistical Analysis

We used software provided by Zeiss for FRET and FCS analysis. For number and brightness analysis we used the SimFCS program described above. For statistical analysis we used SigmaStat (SPSS, INC., Chicago, IL). We compared the values of diffusion coefficient of fluorescent lipids using Kruskal-Wallis One Way Analysis of Variance on Ranks, Dunn's Method, One Way Analysis of Variance, Tukey's Method, and paired t-test (Zar, 1998). We concluded the values are significantly different when $P < 0.05$.

Computational Modeling of Heteromeric Complexes of Opioid Receptors

There are no crystal structures of the opioid receptors in either active or inactive states available to date. Thus, assuming that morphine induces preferentially a conformational active state of μ OR, we were prompted to use computational modeling techniques to generate all-atom models of the *Mus musculus* μ OR in an active conformation, and the *Mus musculus* δ OR in an inactive conformation. Specifically, an inactive conformation of δ OR was obtained using a combination of homology and *ab initio* modeling for the TM (based on the β_2 adrenergic receptor crystal structure corresponding to PDB 2RH1 (23)) and loop regions, respectively. Complete details of the modeling strategy and software used to produce these model structures have been reported elsewhere (24). For the active μ OR conformation, a similar combined homology and *ab initio* modeling strategy was employed, differing in the choice of the template structure for homology modeling of the TM region. Based on the proposed similarity between the recent crystal structures of ligand-free opsin and active GPCR conformations, we used the low-pH opsin crystal structure (PDB: 3CAP (25) (26)) as the basis for homology modeling of the TM region of active μ OR. Due to the absence of a conserved proline residue in TM1 of μ OR, we used the TM1 of the β_2 adrenergic receptor crystal structure (PDB: 2RH1 (23)) as a structural template for this specific helix. We constructed putative three-dimensional (3D) models of μ OR- δ OR

heteromeric tetramers based on inferences from published experimental data (see (27)), and the experimental results reported here. Specifically, we assumed that μ OR- δ OR associations preferentially involve helices TM1, TM4, and/or TM5 to generate 3D models of μ OR- δ OR tetramers that formed symmetric interfaces and complied with the fluorescence data. These models were subjected to energy minimization using the steepest descent algorithm as implemented in GROMACS version 4.0.5 (28), with the Optimized Potentials for Liquid Simulations – All Atom (OPLS-AA) force-field (29).

RESULTS

Changes in the association between μ OR and G protein subunits with morphine treatment

To test the current theory that morphine treatment changes the degree of association between μ OR and G protein subunits, we monitored the change in FRET between μ OR and G proteins. It has been shown that eCFP-G β 1/HA-G γ 7 functions identically to wild type (14), and we found that morphine treatment of cells expressing eYFP- μ OR generates a 10 reduction in 3 H-cAMP levels (Calizo et al, *unpublished*) showing that the transfected constructs we are using are functional.

We co-expressed eYFP- μ OR and eCFP-G β 1/HA-G γ 7 in two neuronal cell lines, Neuro-2a and SK-N-SH at low levels. As expected, in both cell lines the proteins were primarily localized on the plasma membrane with a small amount in intracellular vesicles (e.g. Fig. 1A). The values of FRET were the same in both cell types ($0.38 \pm .04$, $n=23$) and were constant 24 to 72 hours after transfection. These FRET values were unchanged when the proteins were co-expressed with unlabeled G α_i . Even though the value of FRET is independent of protein concentration, we choose cells expressing a low and similar amount of the eCFP and eYFP constructs, although the values were found to within error of each other over an approximate 4 fold range of expression level.

To better understand the values of FRET described above, we measured FRET for a positive control of eCFY and eYFP attached at opposite ends of a dodecameric peptide ($0.80 \pm .03$), and a negative control of free CFP and free YFP molecules ($0.10 \pm .02$) expressed in cells (see (30)). Identical low FRET values were obtained for two non-interacting membrane bound proteins (i.e. eCFP-G α_q and PLC δ 1 (30), and eCFP-PI3K and eYFP-PLC β 1 (19)). Thus, the FRET values seen for μ OR and G β are significant. When we consider that the labeled proteins must compete with endogenous proteins, then our FRET measurements suggest a high level of association. We note that since we are viewing many cells over a period of time, we express FRET as a value that considers variations in the eCFP and eYFP expression (i.e. *NFRET*, see *methods*). Note that this value only refers to FRET that is normalized to the intensity levels of the donor and acceptor rather than normalizing the raw FRET to high and low values.

We determined the response of FRET between eYFP- μ OR and eCFP-G β 1/HA-G γ 7 in Neuro-2a and SK-N-SH with morphine treatment. Continuous treatment with 1 μ M morphine over 24 to 72 hours did not significantly change in the localization of the proteins or their amount on the plasma membrane as assessed by confocal imaging, supporting the notion that morphine desensitization does not involve a decrease in the amount of receptor on the plasma membrane (Fig. 1B). To determine whether morphine affects the degree of association between the receptor and G protein, we measured the change in FRET between eYFP- μ OR and eCFP-G β 1/HA-G γ 7 with morphine treatment. We found a small, but significant, 10% decrease in FRET in both cell lines (Fig. 2). While these data show that morphine treatment does not result in large changes in receptor- G protein interactions, they do imply a relatively small change in receptor G-protein coupling or the local conformation and/or arrangement of the receptor-G protein complex. These results contradict the idea that

the desensitization to morphine tolerance is due to physical uncoupling between μ OR and G protein subunits.

Changes in μ OR oligomerization with morphine treatment

Since morphine does not appear to affect the association between μ OR and G proteins, we determined whether it might cause other changes in the physical environment of the receptor. We first assessed changes in the oligomeric state of μ OR with morphine treatment using FRET. These studies were carried out by co-transfecting Neuro-2a cells with eCFP- μ OR and eYFP- μ OR and monitoring changes in FRET with continuous morphine treatment. We found that the receptors displayed a high degree of FRET (0.47 ± 0.04 , $n=12$) that remained constant over 24–72 hours of morphine treatment. This value of FRET is in line with what would be expected from a mixed population of homo- and hetero-oligomers of the eCFP and eYFP-tagged μ OR. The high value of FRET indicates that a very large population of μ OR receptors exists as oligomers.

Many GPCRs appear to reside in higher order lipid and/or protein domains in the plasma membrane which impact their propensity to oligomerize (e.g. (18)). To determine whether μ OR is contained in higher order complexes, we measured its diffusion in Neuro-2a cells using fluorescence correlation spectroscopy (FCS). Free GPCRs are reported to diffuse at a rate of $1 \times 10^{-9} \text{ cm}^2/\text{s}$ (e.g. (31–33)). We find that the diffusion coefficient of eYFP- μ OR is comparable to these values ($D = 7.3 \pm 0.2 \times 10^{-9} \text{ cm}^2/\text{s}$), suggesting that the receptor does not localize in large complexes that limit its mobility. Rather, the diffusion data suggest that the receptor is in small oligomers, such as dimers or tetramers. Treatment of the cells with $1 \mu\text{M}$ morphine for 24hrs did not affect the diffusion coefficient of the protein.

Co-expression of δ OR induces changes in μ OR environment with morphine

μ OR has been shown to interact with δ OR affecting its signaling properties (8). To determine whether μ OR- δ OR interactions may be affected by morphine, we monitored changes in their association by FRET in Neuro-2a cells. In the absence of morphine, the degree of FRET between eYFP- μ OR and eCFP- δ OR is the same within error of eCFP- μ OR and eYFP- μ OR (0.45 ± 0.03 , $n=8$) supporting the ability of the receptors to form oligomers. This similarity suggests that the formation of μ OR- δ OR heteromers is of the same order as μ OR homomers.

We then determined whether chronic morphine treatment will affect the association between eYFP- μ OR and eCFP- δ OR. Unlike the eYFP- μ OR/eCFP- μ OR homomers, morphine causes a reduction in FRET (Fig. 3A). Note that distributions of FRET values, in both the basal and treated states, are fairly large, reflecting a heterogeneous population of eCFP- δ OR/eYFP- μ OR heteromers. The observation that a substantial population of the receptors is still associated with morphine treatment suggests that either morphine is changing the conformation between eCFP- δ OR and eYFP- μ OR resulting in less Förster transfer, or that it is promoting dissociation of the receptors from higher order complexes.

To determine whether the decrease in eYFP- δ OR and eCFP- μ OR FRET was caused by protein dissociation, we measured the mobility of eYFP- μ OR when co-expressed with unlabeled δ OR in Neuro-2a cells with morphine treatment. We found that in the presence of δ OR, the diffusion of μ OR slows from $7.3 \pm 0.2 \times 10^{-9}$ to $6.0 \pm 0.1 \times 10^{-9} \text{ cm}^2/\text{s}$ suggesting an increase in the size of the protein complex. This change could correlate with a shift of the μ OR population to higher order oligomers. Surprisingly, treatment of cells expressing δ OR and eGFP- μ OR with $1 \mu\text{M}$ morphine for 24 hrs significantly increased the rate of diffusion to $13.6 \times 10^{-9} \text{ cm}^2/\text{s}$. This increase was dose-dependent showing smaller increases (34 and 32%) at intermediate (0.05 and $0.1 \mu\text{M}$) morphine concentrations and a 90% increase at 0.5

μ M morphine. Co-treatment with 1 μ M of the antagonist naloxone blocked changes in diffusion to give values identical to those seen in the absence of morphine. Considering that the diffusion constant is inversely proportional to the square root of the mass, these measurements suggest that morphine disrupts larger complexes of μ OR- δ OR heteromers into smaller species.

Number and Brightness analysis suggests that δ OR promotes morphine-induced dissociation of receptor complexes

To gain insight into the oligomerization state of the complexes, we determined the changes in number and brightness (N&B) of eGFP- μ OR in Neuro-2a cells. N&B is based on analysis of fluorescent fluctuation for each pixel in an image stack. The number of mobile particles and their brightness are obtained from the average intensity and the variance of the intensity in each pixel (22). Non-fluorescent molecules are not observed and immobile molecules produce constant decrease in the intensity that is corrected in the analysis.

To establish the oligomerization of eGFP- μ OR, we first measured free eGFP in Neuro-2a cells. This probe yield a brightness of 30,000 c/m/s² which is routinely obtained in our experimental set-up as well as others (see (22)). However, when we measure the brightness of an eGFP dimer, a value of 46,000 c/m/s² is obtained. This value is substantially less than the expected value of 60,000 c/m/s² for a protein dimer. To determine the reason for the reduced brightness of the eGFP dimer, we prepared cytosolic fractions of HEK293 cells expressing either single eGFP or double eGFP. We find that the anisotropy and emission spectrum of the two probes are identical, suggesting that energy transfer between the eGFP molecules in the double construct does not occur (see (34)). However, we also find that the quantum yield of the double eGFP is ~38% lower than the single mutant, implying that the reduced brightness of the double construct is due to self-quenching of the closely packed eGFP fluorophores. Since the receptors are all labeled on the C-terminus, then we would expect their labels to be similarly close in receptor dimers and obtain a brightness value close to 46,000 c/m/s².

For eGFP- μ OR in Neuro-2a cells, we obtain a brightness of 45,000 c/m/s² which we interpret as corresponding to receptor dimers. Treatment of the cells with morphine shifts a portion of the population to higher values which may correspond to tetramers (Fig. 3B) or a large separation between the subunits resulting in dequenching of the eGFP molecules. Note that the population of receptors that experiences this shift is not large enough to result in a significant shift in the diffusion.

When eGFP- μ OR is co-expressed with unlabeled δ OR in Neuro-2a cells, the brightness is similar to eGFP- μ OR alone (i.e. ~45,000 c/m/s²). Taking into account that we concomitantly observe a slower diffusion, we interpret this value as resulting association of μ OR dimers with at least 2 δ OR monomers to achieve units have the brightness of the eGFP- μ OR dimers with a slower diffusion. The simplest model is the formation of μ OR- δ OR tetramers. We note that the distribution of brightness of the complexes is broad suggesting that they contain 1–3 with an average of 2 μ OR subunits.

Surprisingly, when cells expressing eGFP- μ OR and δ OR are treated with morphine, we find that the brightness of the eGFP- μ OR/ δ OR complexes is substantially reduced to a value that corresponds to approximately a 50–50 mixture of eGFP- μ OR- δ OR dimers and eGFP- μ OR dimers. This apparent dissociation of the mixed receptor complexes with morphine correlates well with the observed increase in mobility as measured by FCS (see above).

G protein subunits may detach from larger complexes with morphine treatment

Both our diffusion and brightness measurements show that μ OR- δ OR complexes dissociate with morphine treatment. Since morphine desensitization may involve decoupling of the receptors with G proteins, we determined whether dissociation of receptor heteromers is accompanied by a change in receptor interactions with G protein subunits. This study was carried out by measuring the change in diffusion with morphine treatment of eGFP-G β 1 in Neuro-2a cells when co-transfected with either unlabeled μ OR alone, or with μ OR and δ OR. As expected, eGFP-G β 1 has similar mobility as eGFP-OR when only μ OR is expressed. However, when Neuro-2a cells are transfected with both μ OR and δ OR, a significant population of eGFP-G β 1 shows increased mobility (Fig. 3C). Keeping in mind that the transfection efficiency of the receptors is ~40%, only ~16% of eGFP-G β 1 would be in cells containing both receptors. The results in Fig. 3C suggest that the population of G β 1 whose mobility increases is localized in cells expressing both receptors. Thus, even though morphine may induce dissociation of a significant population of μ OR- δ OR tetramers, interactions with G proteins are maintained.

Structural Interpretation of Fluorescence Data

Since μ OR and δ OR are so closely related, the varying responses of the homo- and heteromers to morphine were unexpected. We thus took a molecular modeling approach to interpret the fluorescence data in structural terms. The simplest model that best fit the diffusion and brightness data is that the majority of μ OR is dimeric and associates with δ OR to form mixed tetramers. We first generated cartoon permutations of tetrameric μ OR- μ OR and μ OR- δ OR complexes (Fig. 4), based on the assumption that dimeric interfaces of opioid receptors involve preferentially TM1, TM4, and/or TM5, as it is the case for several GPCRs (27). In agreement with most available data, only symmetric TM1-TM1, TM4-TM4, or TM4,5-TM4,5 interfaces (represented in Fig. 4A by filled triangles, squares, and circles, respectively) were considered. Fig. 4A shows possible homomeric arrangements of μ OR in a compact (permutations *iv-v*) or more extended (permutations *i-iii*) configuration. These five arrangements differ in the combination of possible symmetric interfaces within the μ OR- μ OR tetramer. On the other hand, at least 11 alternative symmetric permutations (Fig. 4B) could be considered for μ OR- δ OR heteromeric tetramers. Depending on the different combination of symmetric interfaces (2 for each compact configuration, and 3 for each of the more extended ones) within the tetrameric arrangement, the total number of heteromeric permutations is 29 (8 for compact configurations and 21 for more extended ones). Since our brightness data correspond to complexes that contain 2 eGFP- μ OR, we can eliminate heteromeric permutations 4-7, 10 and 11 of Fig. 4B. Keeping in mind that FRET has a steep distance dependence ($1/R^6$ where R is the distance between the fluorophores) and the R_0 (distance at which 50% of donor intensity is lost to transfer) is 50 Å for the eCFP/eYFP FRET pair (35), we can eliminate permutations 1 and 2 of Fig. 4B since the distance between the μ OR subunits (i.e. 72 and 145 Å, respectively), would not give significant amounts of FRET. Permutation 3 of Fig. 4B can also be eliminated because this model would give different FRET values for eCFP- μ OR/eYFP- μ OR versus eCFP- μ OR/eYFP- δ OR, and this is not observed. Thus, permutations 8 and 9 (boxed in Fig. 4B) are proposed to be the most likely candidates for μ OR- δ OR complexes. Not only would these configurations be consistent with the observed μ OR- μ OR and μ OR- δ OR FRET, they are also consistent with the observation that the complexes contain two μ OR subunits that are close enough to allow self-quenching. Thus, we generated energy-minimized 3D molecular models (Fig. 5) of cartoon configurations 8 and 9 for μ OR- δ OR heteromeric complexes using the 2 possible combinations of interfaces in compact tetramers (see *iv* and *v* in Fig. 4A), and the procedure described in *Methods*. A total of four μ OR- δ OR tetrameric models were built that either exhibited TM4,5-TM4,5 (Figs. 5A and 5C) or TM1-TM1 (Figs. 5B and 5D) heterodimeric interfaces. In these models, δ OR was generated in an inactive conformation based on the

inactive $\beta 2$ adrenergic receptor crystal structure (23), and μ OR was built in an activated conformation, based on the opsin crystal structure (25) (26) (see *Methods*). In the Supplemental data, we present a cytoplasmic view of an overlap between the proposed active model of μ OR (*in red*) and an inactive model of the receptor (*in grey*) based on opsin and the $\beta 2$ adrenergic receptor crystal structures, respectively.

DISCUSSION

Determining the effects of prolonged morphine exposure on receptor organization might serve as a basis for understanding the mechanism of desensitization. The underlying cause of morphine tolerance is not understood but appears to culminate from a number of cellular effects. Several mechanisms of morphine desensitization have been proposed (see (1)) and one of these involves uncoupling between μ OR and G protein signaling cascade (see (5)). Here, we directly measured the ability of morphine to alter G protein – receptor interactions using spectroscopic methods. Although we could not uncover evidence for μ OR-G protein uncoupling, we instead found that prolonged treatment with morphine alters the oligomerization behavior of opioid receptor heteromers. We carried out these studies by expressing fluorescent tagged proteins in neuronal cells, and studied their association and movement. We first monitored the cellular localization of μ OR, and G protein subunits. In accord with other studies, we find that these receptors are plasma membrane localized and remain on the membrane with morphine treatment. This result correlates well with biochemical and pharmacologic studies suggesting that desensitization is not due to a loss in receptor binding sites (see (1)).

We tested the idea that morphine treatment decreases the association between μ OR and G proteins by measuring the changes in FRET between eYFP- μ OR and eCFP-G β 1 in real time in living cells. We used G β 1 for these studies since proteomic data from rat studies show that this protein is down-regulated with morphine addiction (Abul-Husn and Devi, *unpublished*), and since G β subunits do not undergo the large structural changes seen in the activation of G α which could affect the degree of FRET. We used eCFP-G β 1 γ 7 since it has been established to have wild type cell properties (15). We note that FRET values between eCFP-G α i and eYFP- μ OR were unchanged with continuous morphine treatment similar to the behavior seen for G β γ and the receptor, and that over-expression of G α i did not affect the degree of FRET between eYFP- μ OR and eCFP-G β 1. Thus, our experiments show that G proteins remain coupled to μ OR with morphine binding in sharp contrast to the behavior seen for other receptor- G protein systems(36).

The R_0 for the CFP/YFP is 30Å (35), and thus a value of FRET greater than our negative controls will indicate that the proteins are physically associated when we consider the size of the proteins and the similar placement of the fluorescent tags. We note that the large uncertainty in probe orientation, and well as the potential contributions from multiple donors and acceptors, preclude us from drawing accurate distances from our FRET values. FRET studies between μ OR and G β 1 in two different neuronal cell lines suggest very minor changes with morphine treatment. This result argues against the idea that desensitization involves decoupling between receptor and G proteins. Thus, morphine must induce other changes in the receptor that alter its ability to generate cell signals.

Since GPCRs may form oligomers, we focused on the ability of morphine to affect receptor-receptor interactions. Using single point FCS, we find that μ OR displays a diffusion coefficient close to those reported for other GPCRs and small integral membrane proteins (see (18)), suggesting that the receptor is in the form of small oligomers. Addition of morphine does not significantly change this value. It is worthwhile to note that while previous FRAP and single point FCS studies show similar mobilities for GPCRs, different

values can be found using other methods. For example, scanning FCS studies of a GFP-labeled bradykinin type 2 receptor (B2R) over-expressed in HEK293 cells can detect two additional populations with a ten-fold and 100-fold slower diffusion even though PCH analysis show the receptor is diffusing as a homodimer (18). Those results suggest maintenance of a dimeric form of this receptor even when localized in large complexes. In contrast, recent single molecule studies of muscarinic acid receptors in COS cells that followed the fluorescence from a bound ligand showed unrestricted diffusion of the monomeric and dimeric, or possibly dimeric to tetrameric forms of the receptor (37). Similar to previous B2R studies (18), our studies show that the brightness of μ OR matches an eGFP dimer, suggesting a unit of two closely spaced μ OR units. Addition of morphine results in a small increase in brightness without a significant change in mobility. This behavior is consistent with a shift from a predominantly dimeric population to a predominantly tetrameric population.

μ OR is the primary mediator of morphine signals (1). Since its oligomerization with δ OR (8) is upregulated with chronic morphine (11), we studied the interaction between these receptors using fluorescence methods in living cells. μ OR and δ OR were transfected under identical conditions and visual inspection of transfected cells indicate that the two receptors are similarly expressed. It is important to note that in our experiments, we viewed the receptors under over-expressed conditions which may promote and stabilize oligomers. Although this behavior is not observed (see below), we predict that endogenous receptors might have a higher tendency to dissociate under natural conditions due to their lower concentrations.

Our FRET measurements show that in the basal state, μ OR appears to have the same propensity to bind to δ OR as it does to itself, suggesting that both homo- and heteromers form. Interestingly, morphine appears to stabilize μ OR- μ OR tetramers but destabilize μ OR- δ OR tetramers even though our measurements suggest that G proteins remain associated with the receptors in the associated or dissociated states. Rapid dissociation and reassociation of GPCR subunits in membranes has been reported (37,38), and the reduced tendency of liganded - μ OR tetramers to dissociate most likely reflects a stabilization of μ OR contacts that increases its persistence time. To interpret the fluorescence data in a structural context, we first created cartoon permutations of μ OR- μ OR and μ OR- δ OR receptor tetramers containing activated μ OR structures. Based on our fluorescence measurements, we were able to narrow down to four model structures the 29 different possibilities to assemble μ OR and δ OR involving the literature-predicted TM regions at symmetric heteromeric interfaces (e.g., TM1-TM1, TM4-TM4, and TM4,5-TM4,5). These four model structures differed in the presence of TM4,5-TM4,5 or TM1-TM1 at heteromeric interfaces. Although more experiments must be carried out using a series of mutant constructs to discriminate among these structures, these 4 models serve as a basis for a more detailed study of the functional properties of morphine receptors.

It is unclear whether disruption of opioid receptors oligomers is linked to morphine sensitization. Previous studies have shown that chronic morphine treatment leads to increased cell surface expression of μ OR- δ OR heteromers (39) and that dimerization with δ OR leads to changes in the spatio-temporal dynamics of μ OR signaling (5). This behavior was mediated primarily by constitutive recruitment of arrestins to the heteromer. The fact that in this study we find association of G β 1 with the heteromer under chronic morphine treatment suggests that the heteromer represents a multipart signaling complex that allows for the activation of heteromer-specific, distinct signaling pathway. This model could, at least in part, contribute to μ OR desensitization seen during the chronic exposure to morphine.

Our studies showing that morphine treatment does not perturb μ OR subunit interactions or μ OR - G protein interactions, but destabilizes μ OR- δ OR oligomers can be interpreted in light of a recent study showing that activation of δ OR in the heteromer leads to the μ OR degradation rather than recycling in turn diminishing its cellular response (12). One can speculate that the smaller μ OR- δ OR oligomers can transfer into the lysosomal pathway more easily than larger μ OR homomers through more accessible sites for proteolysis or modifications, such as ubiquitination. It is thus possible that the μ OR- δ OR system might be of the prime examples of how the oligomerization state of a GPCR can mediate very different cellular responses.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Abbreviations

μ OR	δ OR, μ , δ opioid receptor
eCFP	eYFP, enhanced cyan or yellow fluorescent protein
FRET	Förster resonance energy transfer
FCS	fluorescence correlation spectroscopy
N&B	number and brightness

References

1. Law PY, Wong YH, Loh HH. Molecular Mechanisms and Regulation of Opioid Receptor Signaling. *Annual Review of Pharmacology and Toxicology*. 2000; 40:389–430.
2. Neer EJ. G proteins: Critical control points for transmembrane signals. *Protein Science*. 1994; 3:3–14. [PubMed: 8142895]
3. Neer E. Heterotrimeric G proteins: organizers of transmembrane signals. *Cell*. 1995; 80:249–257. [PubMed: 7834744]
4. Hildebrandt JD. Role of subunit diversity in signaling by heterotrimeric G proteins. *Biochem Pharmacol*. 1997; 54:325–329. [PubMed: 9278091]
5. Rozenfeld R, Devi LA. Receptor heterodimerization leads to a switch in signaling: β -arrestin2-mediated ERK activation by μ - δ opioid receptor heterodimers. *FASEB J*. 2007; 21:2455–2465. [PubMed: 17384143]
6. Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. *J Cell Sci*. 2003; 116:4867–4869. [PubMed: 14625380]
7. Devi LA. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. *Trends in Pharmacological Sciences*. 2001; 22:532–537. [PubMed: 11583811]
8. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA. A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101:5135–5139. [PubMed: 15044695]
9. Wang D, Sun X, Bohn LM, Sadée W. Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer. *Molecular Pharmacology*. 2005; 67:2173–2184. [PubMed: 15778451]
10. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, Kieffer BL, Basbaum AI. Dissociation of the Opioid Receptor Mechanisms that Control Mechanical and Heat Pain. *Cell*. 2009; 137:1148–1159. [PubMed: 19524516]
11. Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, Lim M, Maillet E, Junek M, Cahill CM, Harkany T, Devi LA. Increased Abundance of Opioid Receptor Heteromers After Chronic Morphine Administration. *Sci Signal*. 2010; 3:ra54. [PubMed: 20647592]

12. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, Li Q, Yang H, Luo J, Li ZY, Wang Q, Lu YJ, Bao L, Zhang X. Facilitation of μ -Opioid Receptor Activity by Preventing μ -Opioid Receptor-Mediated Codegradation. *Neuron*. 2011; 69:120–131. [PubMed: 21220103]
13. Rios C, Gomes I, Devi LA. μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. *British Journal of Pharmacology*. 2006; 148:387–395. [PubMed: 16682964]
14. Hughes TE, Zhang H, Logothetis D, Berlot CH. Visualization of a functional Gaq-green fluorescent protein fusion in living cells. *J Biol Chem*. 2001; 276:4227–4235. [PubMed: 11076942]
15. Hynes TR, Mervine SM, Yost EA, Sabo JL, Berlot CH. Live cell imaging of G_s and the β_2 -adrenergic receptor demonstrate that both α_s and $\beta_1\gamma_7$ internalize upon stimulation and exhibit similar trafficking patterns that differ from that of the β_2 -adrenergic receptor. *J Biol Chem*. 2004; 279:44101–44112. [PubMed: 15297467]
16. Hynes, TR.; Hughes, TE.; Berlot, CH. Cellular localization of GFP-tagged α subunits. In: Smrcka, A., editor. *G Protein Signaling, Methods and Protocols*. Humana Press; Totowa, NJ: 2004.
17. Hein PRF, Hoffmann C, Dorsch S, Nikolaev VO, Engelhardt S, Berlot CH, Lohse M, Buneman M. G_s activation is time-limiting in initiating receptor-mediated signaling. *J Biol Chem*. 2006; 281:33345–33351. [PubMed: 16963443]
18. Philip F, Sengupta P, Scarlata S. Signaling through a G Protein Coupled Receptor and its corresponding G protein follows a stoichiometrically limited model. *J Biol Chem*. 2007; 282:19203–19216. [PubMed: 17420253]
19. Golebiewska U, Scarlata S. $G\{\alpha\}q$ Binds Two Effectors Separately in Cells: Evidence for Predetermined Signaling Pathways. *Biophys J*. 2008; 95:2575–2582. [PubMed: 18515384]
20. Xia Z, Liu Y. Reliable and global measurement of fluorescence resonance energy transfer using fluorescence microscopes. *Biophys J*. 2001; 81:2395–2402. [PubMed: 11566809]
21. Schuille P, Haupts U, Maiti S, Webb WW. Molecular dynamics in living cells observed by fluorescence correlation spectroscopy with one- and two-photon excitation. *Biophys J*. 1999; 77:2251–2265. [PubMed: 10512844]
22. Digman MA, Dalal R, Horwitz AF, Gratton E. Mapping the Number of Molecules and Brightness in the Laser Scanning Microscope. *Biophys J*. 2008; 97:2320–2332. [PubMed: 18096627]
23. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-Resolution Crystal Structure of an Engineered Human 2-Adrenergic G Protein Coupled Receptor. *Science*. 2007; 318:1258–1265. [PubMed: 17962520]
24. Provasi D, Bortolato A, Filizola M. Exploring Molecular Mechanisms of Ligand Recognition by Opioid Receptors with Metadynamics. *Biochemistry*. 2009; 48:10020–10029. [PubMed: 19785461]
25. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krausz N, Choe HW, Hofmann KP, Ernst OP. Crystal structure of opsin in its G-protein-interacting conformation. *Nature*. 2008; 455:497–502. [PubMed: 18818650]
26. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. *Nature*. 2008; 454:183–187. [PubMed: 18563085]
27. Filizola M. Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery? *Life Sciences*. 2009 May 22. [Epub ahead of print].
28. Spoel DVD, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: Fast, flexible, and free. *Journal of Computational Chemistry*. 2005; 26:1701–1718. [PubMed: 16211538]
29. Jorgensen WL, Tirado-Rives J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. *Journal of the American Chemical Society*. 1988; 110:1657–1666.
30. Dowal L, Provitera P, Scarlata S. Stable association between G $\alpha(q)$ and phospholipase C β_1 in living cells. *J Biol Chem*. 2006; 281:23999–24014. [PubMed: 16754659]

31. Henis YI, Hekman M, Elson EL, Helmreich EJ. Lateral motion of beta receptors in membranes of cultured liver cells. *Proc Natl Acad Sci U S A*. 1982; 79:2907–2911. [PubMed: 6123999]
32. Barak LS, Ferguson SS, Zhang J, Martenson C, Meyer T, Caron MG. Internal trafficking and surface mobility of a functionally intact beta2-adrenergic receptor-green fluorescent protein conjugate. *Mol Pharmacol*. 1997; 51:177–184. [PubMed: 9203621]
33. Hegener O, Prenner L, Runkel F, Baader SL, Kappler J, Haberlein H. Dynamics of b2-Adrenergic Receptor-Ligand Complexes on Living Cells. *Biochem*. 2004; 43:6190–6199. [PubMed: 15147203]
34. Runnels LW, Scarlata SF. Theory and application of fluorescence homotransfer to melittin oligomerization. *Biophysical Journal*. 1995; 69:1569–1583. [PubMed: 8534828]
35. Patterson GH, Piston DW, Barisas BG. Forster distances between green fluorescent protein pairs. *Anal Biochem*. 2000; 284:438–440. [PubMed: 10964438]
36. Freedman NJ, Lefkowitz RJ. Desensitization of G protein-coupled receptors. *Recent Progress in Hormone Research*. 1996; 51:319–351. discussion 352–313. [PubMed: 8701085]
37. Hern JA, Baig AH, Mashanov GI, Birdsall B, Corrie JET, Lazareno S, Molloy JE, Birdsall NJM. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. *Proceedings of the National Academy of Sciences*. 2010; 107:2693–2698.
38. Fonseca JM, Lambert NA. Instability of a Class A G Protein-Coupled Receptor Oligomer Interface. *Molecular Pharmacology*. 2009; 75:1296–1299. [PubMed: 19273553]
39. Décaillot FM, Rozenfeld R, Gupta A, Devi LA. Cell surface targeting of μ - δ opioid receptor heterodimers by RTP4. *Proceedings of the National Academy of Sciences*. 2008; 105:16045–16050.
40. Huang P, Visiers I, Weinstein H, Liu-Chen LY. The Local Environment at the Cytoplasmic End of TM6 of the μ Opioid Receptor Differs from Those of Rhodopsin and Monoamine Receptors: Introduction of an Ionic Lock between the Cytoplasmic Ends of Helices 3 and 6 by a L6.30(275)E Mutation Inactivates the μ Opioid Receptor and Reduces the Constitutive Activity of Its T6.34(279)K Mutant†. *Biochemistry*. 2002; 41:11972–11980. [PubMed: 12356297]
41. Ballesteros, J.; Weinstein, H., editors. Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors. Academic Press; San Diego: 1995.
42. DeLano, WL. The PyMOL Molecular Graphics System DeLano Scientific. San Carlos, CA: 2002.

Fig 1.
Example of images of eCFP-G β 1 (*top left*) and eYFP- μ OR (*top right*), their raw FRET (*bottom left*) and their normalized FRET (*bottom right*) in Neuro-2a cells. Images are artificially colorized by Zeiss software.

Changes in the normalized FRET between eCFP-G β 1 and eYFP- μ OR receptor with 1 μ M morphine relative to control cells where $n = 11-23$.

Fig 2. Percent decrease in eCFP-G β 1 and eYFP- μ OR FRET with continuous 1 μ M morphine treatment where the values were normalized to 0.038 for SKNSN and 0.036 for Neuro-2a cells.

Fig. 3A

Fig. 3B

Fig. 3C

Diffusion of eGFP-G β 1 in Neuro2A cells with morphine treatment **Fig 3.**

A Change in the normalized FRET between eYFP- μ OR and eCFP- δ OR with 1 μ M morphine treatment in Neuro-2a cells. **B** – Change in the molecular brightness in eYFP- μ OR homomers and non-fluorescence δ OR heteromers in Neuro-2a cells. **C** – Change in the distribution of diffusion coefficients of eGFP-G β 1 co-expressed with μ OR- δ OR in Neuro-2a cells with 1 μ M morphine treatment for 48 hours.

Fig 4.

Possible configurations of μOR - μOR and μOR - δOR tetramers. **A**- Cartoon of the possible permutations for the μOR homomeric tetramer. The compact (*iv-v*) and more extended (*i-iii*) arrangements differ in the combination of alternative dimeric interfaces within the tetramer: TM1-TM1 ($\blacktriangle$), TM4-TM4 ($\blacksquare$), and TM4,5-TM4,5 ($\bullet$). **B**- Cartoon of the possible permutations for the heteromeric tetramer formed by μOR (red oval) and δOR (blue oval). Depending on the different combination of symmetric interfaces (2 for compact configurations and 3 for more extended ones) within the tetrameric arrangement, the total number of heteromeric permutations is 29 ($4 \times 2 = 8$ compact and $7 \times 3 = 21$ extended configurations). Permutations 8 and 9 (boxed in the figure) are the most likely candidates for μOR - δOR complexes based on consistency with the observed μOR - μOR and μOR - δOR FRET.

Fig 5.

Energy minimized 3D molecular models of permutations 8 and 9 (from Fig. 4B). **A** and **B** - Models of permutation 8 exhibiting symmetric interaction of TM4,5 or TM1, respectively, at the heterodimeric μ OR- δ OR interface. **C** and **D**) Models of permutation 9 exhibiting symmetric interaction of TM4,5 or TM1, respectively, at the heterodimeric μ OR- δ OR interface. In all cases, μ OR is shown in red and δ OR is shown in blue.